| Overview |
| bs-1972R-PE-Cy5 |
| LCAT Polyclonal Antibody, PE-Cy5 Conjugated |
| WB |
| Human, Mouse, Rat |
| Dog, Cow, Pig, Horse, Rabbit |
| Specifications |
| PE-Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human LCAT |
| 151-250/440 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 3931 |
| P04180 |
| Secreted |
| Phosphatidylcholine-sterol acyltransferase; Lecithin-cholesterol acyltransferase; Phospholipid-cholesterol acyltransferase; LCAT |
| Central enzyme in the extracellular metabolism of plasma lipoproteins. Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low density lipoproteins (HDLs and LDLs). The cholesterol ester is then transported back to the liver. Has a preference for plasma 16:0-18:2 or 18:O-18:2 phosphatidylcholines. Also produced in the brain by primary astrocytes, and esterifies free cholesterol on nascent APOE-containing lipoproteins secreted from glia and influences cerebral spinal fluid (CSF) APOE- and APOA1 levels. Together with APOE and the cholesterol transporter ABCA1, plays a key role in the maturation of glial-derived, nascent lipoproteins. Required for remodeling high-density lipoprotein particles into their spherical forms. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz